Zydus Wellness Ltd

Zydus Wellness Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Zydus Wellness Ltd

₹ 1,751 1.28%
15 May 4:01 p.m.
zyduswellness.in BSE: 531335 NSE: ZYDUSWELL
About

Zydus Wellness operates as an integrated consumer Company with business encompassing the entire value chain in the development, production, marketing and distribution of health and wellness products. The product portfolio of the Company includes brands like Sugar free, Everyuth and Nutralite.(Source : 202003 Annual Report Page No: 83)

Key Points

Product Portfolio
The Company’s product portfolio includes brands like Glucon-D, Complan, Sugar-Free, Nycil, Everyuth, and Nutralite offering products such as Glucose Powder, Face wash, Scrub, Peel-Off, Face masks, Sugar Substitute, Blended Sugar, etc [1]

Website BSE NSE
  • Market Cap ₹ 11,198 Cr.
  • Current Price ₹ 1,751
  • High / Low ₹ 1,791 / 1,425
  • Stock P/E 39.8
  • Book Value ₹ 842
  • Dividend Yield 0.28 %
  • ROCE 5.37 %
  • ROE 5.36 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is almost debt free.

Cons

  • Tax rate seems low
  • Company has a low return on equity of 6.09% over last 3 years.
  • Dividend payout has been low at 10.8% of profits over last 3 years
  • Debtor days have increased from 34.6 to 44.4 days.
  • Working capital days have increased from 61.6 days to 88.8 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: FMCG Industry: Food - Processing - Indian

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
606 598 384 388 640 696 429 416 713 702 440 403 783
460 457 353 356 498 548 413 388 568 586 423 390 620
Operating Profit 145 140 31 32 142 148 16 28 145 116 17 13 162
OPM % 24% 24% 8% 8% 22% 21% 4% 7% 20% 17% 4% 3% 21%
2 2 3 3 2 -1 1 1 -6 -12 4 3 4
Interest 8 6 7 6 6 4 3 4 5 5 6 6 6
Depreciation 6 6 6 6 6 6 6 6 7 6 6 6 6
Profit before tax 133 131 21 23 131 137 8 19 126 93 9 4 154
Tax % -0% -0% -2% -3% -1% -0% -4% -1% -15% -18% 31% 92% 3%
133 131 21 23 133 137 8 20 145 110 6 0 150
EPS in Rs 20.92 20.56 3.37 3.66 20.95 21.53 1.34 3.08 22.83 17.35 0.93 0.05 23.62
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
388 404 431 397 431 513 843 1,767 1,867 2,009 2,255 2,328
291 319 331 305 331 387 658 1,446 1,522 1,664 1,918 2,020
Operating Profit 97 85 100 91 99 125 185 321 344 345 337 308
OPM % 25% 21% 23% 23% 23% 24% 22% 18% 18% 17% 15% 13%
16 19 28 32 32 35 28 -33 -123 10 -5 -0
Interest 0 0 0 0 1 2 30 140 84 26 16 24
Depreciation 4 -0 8 7 7 9 13 26 25 24 25 24
Profit before tax 108 104 120 117 124 150 171 121 112 306 291 260
Tax % 8% 5% 7% 10% 10% 9% -0% -17% -6% -1% -7% -3%
99 98 111 105 111 137 171 142 119 309 310 267
EPS in Rs 24.85 24.69 27.88 26.43 27.89 34.27 29.33 24.58 18.66 48.54 48.78 41.94
Dividend Payout % 24% 24% 22% 25% 23% 23% 17% 20% 27% 10% 10% 12%
Compounded Sales Growth
10 Years: 19%
5 Years: 23%
3 Years: 8%
TTM: 3%
Compounded Profit Growth
10 Years: 11%
5 Years: 12%
3 Years: 4%
TTM: -12%
Stock Price CAGR
10 Years: 13%
5 Years: 7%
3 Years: -6%
1 Year: 14%
Return on Equity
10 Years: 7%
5 Years: 6%
3 Years: 6%
Last Year: 5%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 39 39 39 39 39 39 58 58 64 64 64 64
Reserves 217 286 367 439 518 652 3,329 3,403 4,504 4,780 5,059 5,294
-0 -0 -0 -0 25 25 1,569 1,519 550 387 297 329
93 99 102 89 100 112 503 610 548 461 413 462
Total Liabilities 349 425 508 568 682 829 5,459 5,590 5,666 5,692 5,833 6,148
94 95 84 82 103 104 4,567 4,674 4,667 4,710 4,732 4,708
CWIP -0 0 0 0 0 0 10 4 4 12 13 10
Investments -0 5 -0 94 30 148 46 110 -0 27 70 78
255 324 423 391 550 577 835 802 995 943 1,018 1,354
Total Assets 349 425 508 568 682 829 5,459 5,590 5,666 5,692 5,833 6,148

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
69 91 69 90 77 69 149 259 287 237 92 246
13 13 29 -28 -72 -59 -4,092 -17 -10 -59 -85 -19
-23 -27 -27 -58 -6 -2 4,052 -260 -216 -234 -138 -26
Net Cash Flow 59 77 71 4 -1 8 109 -18 60 -56 -132 201

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 1 2 1 3 3 6 42 24 18 26 34 44
Inventory Days 120 108 76 73 127 113 393 168 158 135 146 150
Days Payable 136 191 146 191 264 254 662 289 189 136 100 116
Cash Conversion Cycle -14 -82 -69 -116 -134 -135 -227 -97 -13 25 80 78
Working Capital Days -32 -48 -37 -38 -36 -8 4 -3 12 31 65 89
ROCE % 48% 35% 32% 26% 23% 22% 7% 6% 6% 6% 6%

Shareholding Pattern

Numbers in percentages

3 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
64.82% 64.82% 64.82% 64.82% 65.14% 65.36% 65.36% 66.45% 67.11% 68.54% 69.15% 69.62%
2.96% 2.94% 3.39% 2.56% 2.38% 3.24% 3.83% 3.87% 3.23% 3.42% 3.25% 3.26%
24.76% 25.49% 24.80% 25.11% 25.11% 23.78% 23.35% 22.18% 22.04% 20.22% 19.67% 19.41%
7.46% 6.75% 6.99% 7.51% 7.37% 7.62% 7.46% 7.51% 7.62% 7.81% 7.91% 7.71%
No. of Shareholders 58,03555,51359,82367,20866,84570,70968,96970,79073,02976,59075,36969,138

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls